Coreen Schwartzlow1, Mohamed Kazamel2. 1. Department of Neurology, University of Alabama at Birmingham, 1720 2nd Ave. South, SC271, Birmingham, AL, USA. 2. Department of Neurology, University of Alabama at Birmingham, 1720 2nd Ave. South, SC271, Birmingham, AL, USA. mkazamel@uabmc.edu.
Abstract
PURPOSE OF REVIEW: Hereditary sensory and autonomic neuropathies (HSANs) are a clinically heterogeneous group of inherited neuropathies featuring prominent sensory and autonomic involvement. Classification of HSAN is based on mode of inheritance, genetic mutation, and phenotype. In this review, we discuss the recent additions to this classification and the important updates on management with a special focus on the recently investigated disease-modifying agents. RECENT FINDINGS: In this past decade, three more HSAN types were added to the classification creating even more diversity in the genotype-phenotype. Clinical trials are underway for disease-modifying and symptomatic therapeutics, targeting mainly HSAN type III. Obtaining genetic testing leads to accurate diagnosis and guides focused management in the setting of such a diverse and continuously growing phenotype. It also increases the wealth of knowledge on HSAN pathophysiologies which paves the way toward development of targeted genetic treatments in the era of precision medicine.
PURPOSE OF REVIEW: Hereditary sensory and autonomic neuropathies (HSANs) are a clinically heterogeneous group of inherited neuropathies featuring prominent sensory and autonomic involvement. Classification of HSAN is based on mode of inheritance, genetic mutation, and phenotype. In this review, we discuss the recent additions to this classification and the important updates on management with a special focus on the recently investigated disease-modifying agents. RECENT FINDINGS: In this past decade, three more HSAN types were added to the classification creating even more diversity in the genotype-phenotype. Clinical trials are underway for disease-modifying and symptomatic therapeutics, targeting mainly HSAN type III. Obtaining genetic testing leads to accurate diagnosis and guides focused management in the setting of such a diverse and continuously growing phenotype. It also increases the wealth of knowledge on HSAN pathophysiologies which paves the way toward development of targeted genetic treatments in the era of precision medicine.
Entities:
Keywords:
Congenital insensitivity to pain; Familial dysautonomia; Hereditary sensory and autonomic neuropathies; IKBKAP/ELP1; L-Serine
Authors: M Nolano; C Crisci; L Santoro; F Barbieri; R Casale; W R Kennedy; G Wendelschafer-Crabb; V Provitera; N Di Lorenzo; G Caruso Journal: Clin Neurophysiol Date: 2000-09 Impact factor: 3.708
Authors: S A Slaugenhaupt; A Blumenfeld; S P Gill; M Leyne; J Mull; M P Cuajungco; C B Liebert; B Chadwick; M Idelson; L Reznik; C Robbins; I Makalowska; M Brownstein; D Krappmann; C Scheidereit; C Maayan; F B Axelrod; J F Gusella Journal: Am J Hum Genet Date: 2001-01-22 Impact factor: 11.025
Authors: S L Anderson; R Coli; I W Daly; E A Kichula; M J Rork; S A Volpi; J Ekstein; B Y Rubin Journal: Am J Hum Genet Date: 2001-01-22 Impact factor: 11.025
Authors: Annette Lischka; Petra Lassuthova; Arman Çakar; Christopher J Record; Jonas Van Lent; Jonathan Baets; Maike F Dohrn; Jan Senderek; Angelika Lampert; David L Bennett; John N Wood; Vincent Timmerman; Thorsten Hornemann; Michaela Auer-Grumbach; Yesim Parman; Christian A Hübner; Miriam Elbracht; Katja Eggermann; C Geoffrey Woods; James J Cox; Mary M Reilly; Ingo Kurth Journal: Nat Rev Dis Primers Date: 2022-06-16 Impact factor: 65.038
Authors: Rose M Follis; Chhavy Tep; Thiago C Genaro-Mattos; Mi Lyang Kim; Jae Cheon Ryu; Vivianne E Morrison; Jonah R Chan; Ned Porter; Bruce D Carter; Sung Ok Yoon Journal: J Neurosci Date: 2021-09-10 Impact factor: 6.167